"Naltrexone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
| Descriptor ID |
D009271
|
| MeSH Number(s) |
D03.132.577.249.706.550 D03.605.497.750.550 D03.633.400.686.750.550 D04.615.723.795.706.550
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Naltrexone".
Below are MeSH descriptors whose meaning is more specific than "Naltrexone".
This graph shows the total number of publications written about "Naltrexone" by people in this website by year, and whether "Naltrexone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 0 | 2 |
| 2007 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2022 | 0 | 3 | 3 |
| 2024 | 1 | 0 | 1 |
| 2025 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Naltrexone" by people in Profiles.
-
Cowan E, O'Brien-Lambert C, Eiting E, Bull E, Ryder J, Calderon Y, Salsitz E. Emergency department-initiated oral naltrexone for patients with moderate to severe alcohol use disorder: A pilot feasibility study. Acad Emerg Med. 2025 05; 32(5):488-497.
-
Quintanilla ME, Israel Y. Role of Metabolism on?Alcohol Preference, Addiction, and Treatment. Curr Top Behav Neurosci. 2025; 71:193-216.
-
Noverati N, Mehta S, Reed MK, Zavodnick J. Understanding Barriers and Assessing Education Intervention on Prescribing Naltrexone for Alcohol Use Disorder. Am J Med Qual. 2024 Jul-Aug 01; 39(4):197-198.
-
Ayyala D, Bottyan T, Tien C, Pimienta M, Yoo J, Stager K, Gonzalez JL, Stolz A, Dodge JL, Terrault NA, Han H. Naltrexone for alcohol use disorder: Hepatic safety in patients with and without liver disease. Hepatol Commun. 2022 12; 6(12):3433-3442.
-
Kay A, Shmuts R, Beck M. Understanding and co-managing medication treatment options for opioid use disorder. Intern Emerg Med. 2022 10; 17(7):2159-2165.
-
Beauchamp GA, Hanisak JL, Amaducci AM, Koons AL, Laskosky J, Maron BM, McLoughlin TM. Perioperative Management of Patients on Maintenance Medication for Addiction Treatment: The Development of an Institutional Guideline. AANA J. 2022 02; 90(1):50-57.
-
Quintanilla ME, Rivera-Meza M, Berrios-C?rcamo PA, Bustamante D, Buscaglia M, Morales P, Karahanian E, Herrera-Marschitz M, Israel Y. Salsolinol, free of isosalsolinol, exerts ethanol-like motivational/sensitization effects leading to increases in ethanol intake. Alcohol. 2014 Sep; 48(6):551-9.
-
Brailoiu GC, Deliu E, Hooper R, Dun NJ, Undieh AS, Adler MW, Benamar K, Brailoiu E. Agonist-selective effects of opioid receptor ligands on cytosolic calcium concentration in rat striatal neurons. Drug Alcohol Depend. 2012 Jun 01; 123(1-3):277-81.
-
Salamina G, Diecidue R, Vigna-Taglianti F, Jarre P, Schifano P, Bargagli AM, Davoli M, Amato L, Perucci CA, Faggiano F. Effectiveness of therapies for heroin addiction in retaining patients in treatment: results from the VEdeTTE study. Subst Use Misuse. 2010 Oct; 45(12):2076-92.
-
Ward SJ, Roberts DC. Microinjection of the delta-opioid receptor selective antagonist naltrindole 5'-isothiocyanate site specifically affects cocaine self-administration in rats responding under a progressive ratio schedule of reinforcement. Behav Brain Res. 2007 Aug 22; 182(1):140-4.